Manuka Resources to restart Wonawinta silver and gold production in 2026
Manuka Resources (ASX:MKR) is on track to restart silver and gold production at its 100% owned Wonawinta facility in New South Wales in the second quarter of 2026.
Manuka Resources (ASX:MKR) is on track to restart silver and gold production at its 100% owned Wonawinta facility in New South Wales in the second quarter of 2026.
Summit Minerals (ASX:SUM) announced plans to seek shareholder approval at its upcoming general meeting to change its name to Western Ridge Resources.
SQX Resources (ASX:SQX) reports a major milestone for its 80%-owned subsidiary AM6, having received final approval from the US Bureau of Land Management to commence site works and drilling at the Red Bird Gold Project in Arizona.
Almonty Industries (ASX:AII), a global tungsten producer, has appointed financial veteran Guillaume Wiesenbach de Lamaziere, CFA, as Chief Development Officer.
WiseTech Global (ASX:WTC) has signed a non-binding memorandum of understanding with US-based logistics company ELM Global to support the digital transformation of Saudi Arabia’s logistics sector.
Titanium Sands (ASX:TSL) has lodged applications for an industrial mining licence for the proposed development of its Mannar Heavy Minerals Project,
Australian antiviral developer Island Pharmaceuticals (ASX:ILA) has been granted US Patent Number 12,508,266 by the US Patent and Trademark Office for the use of Galidesivir.
Pure Resources (ASX:PR1) has confirmed graphite as a critical input for advanced thermal management applications.
Prices in Sydney and Melbourne have dipped for the first time in months, catching boom-time bulls off guard.
Askari Metals (ASX:AS2) has strengthened its balance sheet by fully repaying its convertible note facility with Lawson Mining and settling all Series B redeemable notes.
3D Energi (ASX:TDO) has reported that its Charlemont-1 gas exploration well, located approximately 55km offshore from Port Campbell in Victoria's Otway Basin.
Neuren Pharmaceuticals (ASX:NEU) announced that results from its Phase 2 clinical trial of NNZ-2591 in children and adolescents with Phelan-McDermid syndrome have been published in Neurology Genetics